Azilsartan is a Next Generation ARB Blockbuster

Azilsartan is a Next Generation ARB Blockbuster

AzilsartanOn February 25, 2011 the FDA approved Azilsartan for the treatment of hypertension. Known as the brand name Edarbi marketed by Takeda Pharmaceuticals, Azilsartan has shown to be extremely effective in clinical studies. When compared with other FDA approved medications for hypertension, particularly valsartan (Diovan) and olmesartan (Benicar), Azilsartan (Edarbi) proved to be more efficacious than its competitors by lowering blood pressure rates faster in a 24 hour period, as well as keeping these rates low. As an angiotensin II receptor blocker, or ARB, Azilsartan lowers blood pressure by blocking the action of angiotensin II, which is a vasopressor hormone. Azilsartan is offered in 80 mg and 40 mg dosages, with the recommended dose of 80 mg once daily for adults with hypertension. Patients who are also taking high-dose diuretics to reduce salt in their body will likely receive the 40 mg dose. Adverse effects of Azilsartan tent to be mild, and may include dizziness or a faint feeling.

With so many medications on the market to treat hypertension, you may be asking yourself why the FDA would approve yet another one. The fact remains that hypertension is statistically inadequately controlled, according to the Formulary Journal.  More than half of the patient population who are  diagnosed with hypertension today fail to find efficacy with the current drugs on the market today. As a newer-generation ARB with formidable antihypertensive effects, Azilsartan is successful at treating patients not only with hypertension, but also by offering antidiabetic and cardioprotective benefits. With one in three adults in the United States suffering from hypertension, or high blood pressure, the need for novel and comprehensive treatments are essential.

LGM Pharma provides Azilsartan CAS# 147403-03-0 for research and development purposes. Clients can rely on LGM Pharma for continuous support throughout the R&D process. The worldwide number of people estimated by the FDA to have hypertension in 2025 is a staggering 1.5 billion. The time is now to develop efficient and dynamic products to combat this often deadly disease.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service